康哲藥業(00867.HK)簽訂合作協議 獲智翔金泰兩產品獨家許可權
康哲藥業(00867.HK)公佈,透過附屬與重慶智翔金泰簽訂獨家合作協議,據此,集團獲得唯康度塔單抗注射液及斯樂韋米單抗注射液在中國的獨家商業化權與除中國之外的亞太地區及中東、北非的獨家許可權。
唯康度塔單抗注射液是一款由智翔金泰自主研發的重組人源化抗破傷風毒素的單克隆抗體,2024年5月獲國家藥品監督管理局藥品審評中心納入突破性治療品種名單。斯樂韋米單抗注射液是一款由智翔金泰自主研發的重組全人源抗狂犬病病毒雙特異性抗體,目前正在進行III期臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.